Colchicine Dosing Recommendations for Gout Management

Acute Gout Flare Treatment

Low‑dose regimen (1.2 mg then 0.6 mg one hour later, total 1.8 mg) is as effective as the traditional high‑dose 4.8 mg over 6 h but produces far fewer gastrointestinal adverse events. (American College of Rheumatology) [1][2]3
Start colchicine within 12 hours of flare onset to achieve optimal symptom control. (American College of Rheumatology) [1][4]
Colchicine is contraindicated when co‑administered with strong P‑glycoprotein or CYP3A4 inhibitors (e.g., cyclosporine, clarithromycin, ritonavir, ketoconazole). (American College of Rheumatology) [1][4]
Avoid colchicine in patients with severe renal impairment (creatinine clearance < 30 mL/min or on dialysis). (American College of Rheumatology) [1][4]
High‑dose hourly colchicine regimens are obsolete and associated with dangerous toxicity; they should never be used. (American College of Rheumatology) 2

Prescribe colchicine 0.5–1 mg daily (U.S. practice: 0.6 mg once or twice daily) for at least 6 months when starting urate‑lowering therapy. (American College of Rheumatology) [1][4][5][6]
The 2020 ACR guideline strongly recommends continuing prophylaxis for 3–6 months rather than a shorter duration, with ongoing assessment if flares persist. (American College of Rheumatology) 6
Minimum prophylaxis duration is 6 months for all patients initiating urate‑lowering therapy. (American College of Rheumatology) [1][5]6
If the serum urate target is reached and no tophi are present, extend prophylaxis for an additional 3 months. (American College of Rheumatology) [5][7]
If tophi are present, extend prophylaxis for an additional 6 months after achieving the urate target. (American College of Rheumatology) [5][7]

In moderate renal impairment (creatinine clearance 30–50 mL/min), reduce prophylactic colchicine to 0.3 mg once daily or 0.6 mg every other day. (American College of Rheumatology) [1][4]

Elderly patients should often start prophylaxis at a lower dose (0.3 mg daily) because of age‑related renal decline. (American College of Rheumatology) 5
Elderly patients receiving statins require close monitoring for neuromuscular toxicity. (American College of Rheumatology) [1][4]

If an acute gout flare occurs in a patient already on colchicine prophylaxis, colchicine should not be used for acute treatment; instead choose an NSAID or corticosteroid. (American College of Rheumatology) [8][7]

Co‑administration of colchicine with strong CYP3A4 or P‑glycoprotein inhibitors in any patient with renal or hepatic impairment is prohibited due to reports of fatal toxicity. (American College of Rheumatology) [1][4]
Statin use together with colchicine in patients with renal impairment markedly raises the risk of neuromuscular toxicity. (American College of Rheumatology) [1][4]
In severe renal impairment (creatinine clearance < 30 mL/min), colchicine should not be used for acute gout flares; corticosteroids are the preferred alternative. (American College of Rheumatology) [1][4]

Initiating colchicine within 36 hours of symptom onset provides optimal efficacy; if treatment is started later, an NSA or corticosteroid should be preferred. 9

In individuals already receiving prophylactic colchicine, colchicine should not be used for acute flare treatment; an NSA or corticosteroid is recommended instead. 9

Begin colchicine prophylaxis at 0.6 mg once daily or twice daily (maximum 1.2 mg/day) at the time of, or just before, initiating ULT. 9

Continue colchicine prophylaxis for at least 6 months after ULT initiation. 9
If no tophi are present and the serum urate target is achieved, extend prophylaxis for an additional 3 months beyond reaching target. 9
If tophi are present, extend prophylaxis for an additional 6 months after achieving the urate target. 9

For patients with severe renal impairment (creatinine clearance < 30 mL/min), start prophylactic colchicine at 0.3 mg twice weekly, with close monitoring. 9